Avanos Q2 net sales $186M (+14% YoY); guides FY adj. EPS to $1.10–$1.20 from $1.10–$1.25

AVANOS MEDICAL, INC.

2021-Q2 EPS reported $0.62 revenue$367,100,000

Q2 diluted EPS $0.78 vs. loss of $0.06; adjusted diluted EPS $0.21 vs. $0.13.
Gross margin fell to 46% (59% adj.) due to higher freight and manufacturing inefficiencies.
Full-year net sales growth outlook maintained at 2%–4% constant currency; adj. EPS guidance narrowed to $1.10–$1.20.
Entered Deferred Prosecution Agreement with DOJ on July 6 resolving criminal investigation into MicroCool surgical gowns.
Board member Heidi Kunz resigned July 29 to pursue other opportunities; no disagreements.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Heidi Kunz

Director

AVNS · AVANOS MEDICAL, INC.

Effective: 2021-07-29
Filed: August 3, 2021, 7:59 PM ET

On July 29, 2021, Heidi Kunz notified the Company that she was resigning from the Board of Directors to pursue other business opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Heidi Kunz resigned as Director at AVANOS MEDICAL, INC..

Action: resigned
Role: Director

Exact text from the filing

On July 29, 2021, Heidi Kunz notified the Company that she was resigning from the Board of Directors to pursue other business opportunities.

View on SEC.gov

AVANOS MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001606498-21-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.